Low-density lipoprotein apheresis is associated with removal of SARS-CoV-2 antibodies

Ther Apher Dial. 2022 Dec;26(6):1289-1295. doi: 10.1111/1744-9987.13842. Epub 2022 Apr 7.

Abstract

Background: Low-density lipoprotein apheresis is not specific to lipoproteins but removes immunoglobulins as well. It remains elusive, whether protective SARS-CoV-2 antibodies after vaccination from COVID-19 are eliminated as well.

Methods: A cross-sectional case-control study on 55 patients undergoing weekly lipoprotein apheresis and 21 patients with comparable comorbidities and epidemiology not undergoing apheresis. SARS-CoV-2 IgG was assessed in all patients prior to apheresis and in 38 patients both before and after apheresis.

Results: SARS-CoV-2 IgG concentrations before a session of lipoprotein apheresis were comparable to control patients not undergoing apheresis(1727 IU/ml, IQR 365-2500) vs. 1652 IU/ml,(IQR408.8-2500), p = 0.78). SARS-CoV-2 IgG concentrations were reduced by lipoprotein apheresis from 1656 IU/ml(IQR 540.5-2500) prior to 1305 IU/ml (IQR 449-2500) afterwards(p < 0.0001).

Conclusion: Lipoprotein apheresis removes SARS-CoV-2 IgG. The average elimination rate was 21.2%. In the present population of patients undergoing apheresis once weekly, however, the elimination did not lead to inferior concentrations compared to patients not undergoing lipoprotein apheresis.

Keywords: SARS-CoV-2; antibodies; coronavirus disease 2019; low-density lipoprotein apheresis; vaccination.

MeSH terms

  • Blood Component Removal*
  • COVID-19* / therapy
  • Case-Control Studies
  • Cross-Sectional Studies
  • Humans
  • Immunoglobulin G
  • Lipoproteins
  • Lipoproteins, LDL
  • SARS-CoV-2

Substances

  • Lipoproteins
  • Lipoproteins, LDL
  • Immunoglobulin G